Mobile website
Archive > Volume 31 Issue 7 > 2024,31(7):707-714. DOI:10.3872/j.issn.1007-385X.2024.07.010 Prev Next
Clinical Research
Bioinformatic screening reveals the significance of MFAP2 in the prognosis and immunotherapy of gastric cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To screen the key genes affecting the prognosis and treatment of gastric cancer (GC) patients and to analyze the value of the key gene microfibrillar-associated protein 2 (MFAP2) in suggesting the prognosis and the sensitivity of immunotherapy of GC patients. Methods: The expression profile data and clinical information of gastric cancer and paracancerous tissues were downloaded from the TCGA database. Genes significantly associated with the prognosis of gastric cancer were screened by weighted gene co-expression network analysis (WGCNA) and univariate Cox regression analysis. Multiple patient cohorts were used to assess the prognostic value of the key gene MFAP2 and analyze its efficacy and clinicopathological correlation. Multiple online databases and algorithms were used to analyze the correlation between MFAP2 and the tumor immune microenvironment. Immunophenotyping score (IPS) combined with immunotherapy patient cohort was used to analyze the value of MFAP2 in predicting the responsiveness of immunotherapy. Differential expression of MFAP2 in gastric cancer and adjacent tissues was verified with multiple datasets. Results: The blue module showed the highest correlation with survival outcomes of GC patients (R=0.17, PHR>1, PPPConclusion: High expression of MFAP2 is a predictive factor for poor prognosis and response to immunotherapy in GC patients. MFAP2 is expected to serve as a novel therapeutic target and prognostic indicator for gastric cancer.
Keywords:
Project Supported:
Clc Number:
